Actively Recruiting
Study of BAY3498264 Combined With Sotorasib for Advanced Solid Tumors With KRASG12C Mutation
Led by Bayer · Updated on 2026-10-20
104
Participants Needed
11
Research Sites
19 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are investigating treatments for people with advanced solid tumors that have a specific genetic mutation called KRASG12C. The study focuses on evaluating a new drug, BAY3498264, which targets the SOS1 protein that interacts with KRAS, alongside an existing approved drug called sotorasib. This first-in-human study aims to find out how safe BAY3498264 is when combined with sotorasib and to determine the highest safe dose of BAY3498264 in this combination. Participants will receive BAY3498264 alone for the first seven days, followed by cycles of 21 days where they take BAY3498264 together with daily sotorasib. The study has three parts dose escalation to find the right dose, backfill cohorts to gather additional safety and drug data, and exploratory expansion cohorts to further assess safety and effectiveness. Treatment continues as long as it remains beneficial without severe problems or until the cancer progresses. Throughout the study, researchers will collect blood and urine samples, perform imaging scans such as CT, PET, MRI, and X-rays, and monitor heart health using electrocardiograms. They will track side effects, drug levels in the blood, and tumor responses regularly. Participant health is closely monitored during treatment, and safety is assessed up to about 30 to 35 days after the last dose, with the whole study expected to last approximately three years.
CONDITIONS
Brief Title
A Phase I Study of BAY3498264 Given Together With Sotorasib in Participants Who Have Advanced Solid Cancers With Specific Genetic Changes Called KRASG12C Mutation
Research Team
B
Bayer Clinical Trials Contact
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here